摘要
以Meta分析方法系统评价心脉隆注射液对心力衰竭患者临床疗效及血管内皮功能及炎症因子的影响。方法 计算机检索Cochrane图书馆、Embase、PubMed、维普数据库(VIP),万方数据库(WF)和中国知网等数据库,检索时限从建库至2020年12月,有关心脉隆注射液治疗心力衰竭全部的随机对照试验(RCT);以临床有效率、脑钠肽(BNP)指标/N-端脑钠肽前体(NT-proBNP)、高敏C-反应蛋白(hs-CRP)、白介素-10(IL-10)、血管内皮生长因子(VEGF)为结局,采用RevMan5.3软件进行Meta分析。结果 对纳入文献的共1414例患者进行荟萃分析。Meta分析结果显示:心脉隆注射液在降低BNP指标[MD=-158.31,95%CI(-165.63,-150.98),P<0.000 01]/NT-proBNP [MD=-478.27,95%CI(-498.45,-458.09),P<0.000 01],下调hs-CRP指标[MD=-0.42,95%CI(-0.49,-0.36),P<0.000 01];提高IL-10水平[MD=9.05,95%CI(6.32,11.78),P<0.000 01]及VEGF水平[MD=26.40,95%CI(24.30,28.50),P<0.000 01]方面均优于单纯常规西药治疗;且心脉隆注射液较单纯西药治疗对提高心衰患者临床疗效展现出一定的优势[RR=1.19,95%CI(1.13,1.24),P<0.000 01]。结论 心脉隆注射液对心衰患者有一定临床疗效,能降低BNP/NT-proBNP及hs-CRP指标,且能提高心脏保护因子IL-10及VEGF水平,对心室重构具有一定的预防作用,从而延缓心衰的进一步发生发展。
To evaluate the effect of Xinmailong Injection(心脉隆注射液) on patients with heart failure and the effect of vascular endothelial function and inflammatory factors with a systematic review method.Methods The Cochrane Library, Embase, PubMed, VIP,Wanfang Database(WF) and CNKI and other databases were searched by computer, and the search time limit was from the establishment of the database to December 2020. Randomized controlled trials(RCT) of Xinmailong injection in the treatment of heart failure were collected. The outcomes were clinical effective rate, brain natriuretic peptide(BNP) index/N-terminal pro brain natriuretic peptide(NT proBNP), high-sensitivity C-reactive protein(hs-CRP), interleukin-10(IL-10) and vascular endothelial growth factor(VEGF),and RevMan 5.3 software was used for Meta-analysis.Results A total of 1414 patients included in the literature were Meta-analyzed. Meta-analysis results showed that Xinmailong Injection reduced BNP indexes[MD=-158.31,95%CI(-165.63,-150.98),P<0.000 01]/NT-proBNP[MD=-478.27,95%CI(-498.45,-458.09),P<0.000 01],lowered hs-CRP index[MD=-0.42,95%CI(-0.49,-0.36),P<0.000 01],increased IL-10 level[MD=9.05,95%CI(6.32,11.78),P<0.000 01] and VEGF level [MD=26.40,95%CI(24.30,28.50),P<0.000 01] more obviously than the simple conventional western medicine treatment and Xinmailong Injection compared with pure western medicine treatment. Xinmailong injection showed certain advantages on improving the clinical efficacy of patients with heart failure[RR=1.19,95%CI(1.13,1.24),P<0.000 01].Conclusion Xinmailong Injection has a certain clinical effect on patients with heart failure. It can reduce BNP/NT-proBNP and hs-CRP indicators, and can increase the levels of cardioprotective factors IL-10 and VEGF,and has a certain preventive effect on ventricular remodeling, thereby delaying the further development of heart failure.
作者
王洁
陈勇
杨彤
何德英
任毅
WANG Jie;CHEN Yong;YANG Tong;HE Deying;REN Yi(Guizhou University of Traditional Chinese Medicine,Guiyang 550002,Guizhou,China;Chongqing Traditional Chinese Medicine Hospital,Chongqing 400021,China)
出处
《实用中医内科杂志》
2022年第9期67-70,I0004-I0006,共7页
Journal of Practical Traditional Chinese Internal Medicine
基金
重庆市科研机构绩效激励引导专硕项目(cstc2020jxj1130006)
重庆市名老中医药专家何德英传承工作室建设项目(YAY2020-20)。
